JP2021535727A5 - - Google Patents
Info
- Publication number
- JP2021535727A5 JP2021535727A5 JP2020556258A JP2020556258A JP2021535727A5 JP 2021535727 A5 JP2021535727 A5 JP 2021535727A5 JP 2020556258 A JP2020556258 A JP 2020556258A JP 2020556258 A JP2020556258 A JP 2020556258A JP 2021535727 A5 JP2021535727 A5 JP 2021535727A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- recombinant fusion
- recombinant
- nrg
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097663A JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656246P | 2018-04-11 | 2018-04-11 | |
| US62/656,246 | 2018-04-11 | ||
| PCT/US2019/026889 WO2019200033A1 (en) | 2018-04-11 | 2019-04-11 | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097663A Division JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535727A JP2021535727A (ja) | 2021-12-23 |
| JP2021535727A5 true JP2021535727A5 (enExample) | 2022-04-19 |
| JP7575272B2 JP7575272B2 (ja) | 2024-10-29 |
Family
ID=66484143
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556258A Active JP7575272B2 (ja) | 2018-04-11 | 2019-04-11 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2023097663A Active JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A Pending JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097663A Active JP7631420B2 (ja) | 2018-04-11 | 2023-06-14 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
| JP2025017265A Pending JP2025072502A (ja) | 2018-04-11 | 2025-02-05 | ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11046741B2 (enExample) |
| EP (2) | EP4361177A3 (enExample) |
| JP (3) | JP7575272B2 (enExample) |
| KR (1) | KR102949228B1 (enExample) |
| CN (2) | CN118909141A (enExample) |
| AU (2) | AU2019252262B2 (enExample) |
| BR (1) | BR112020020646A2 (enExample) |
| CA (1) | CA3096420A1 (enExample) |
| CL (1) | CL2020002621A1 (enExample) |
| CO (1) | CO2020012621A2 (enExample) |
| DK (1) | DK3774859T3 (enExample) |
| EA (1) | EA202092458A1 (enExample) |
| ES (1) | ES2980163T3 (enExample) |
| FI (1) | FI3774859T3 (enExample) |
| HU (1) | HUE066892T2 (enExample) |
| IL (2) | IL322374A (enExample) |
| MX (2) | MX2020010740A (enExample) |
| MY (1) | MY204230A (enExample) |
| PE (1) | PE20210111A1 (enExample) |
| PH (1) | PH12020551648A1 (enExample) |
| PL (1) | PL3774859T3 (enExample) |
| PT (1) | PT3774859T (enExample) |
| SG (1) | SG11202009831UA (enExample) |
| TW (2) | TWI834654B (enExample) |
| WO (1) | WO2019200033A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3774859T3 (fi) | 2018-04-11 | 2024-05-24 | Salubris Biotherapeutics Inc | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| JP2022547335A (ja) * | 2019-09-16 | 2022-11-11 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | 組換えヒトニューレグリン誘導体及びその使用 |
| CN114420310B (zh) * | 2022-01-18 | 2024-11-12 | 河南大学 | 基于图转换网络的药物ATC Code预测方法 |
| AU2023233680A1 (en) * | 2022-03-15 | 2024-10-17 | Salubris Biotherapeutics, Inc. | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
| CN116832040B (zh) * | 2023-06-12 | 2026-01-13 | 北京市心肺血管疾病研究所 | 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用 |
| WO2025122581A1 (en) * | 2023-12-08 | 2025-06-12 | The Trustees Of Indiana University | Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis |
| WO2025245112A1 (en) | 2024-05-21 | 2025-11-27 | Salubris Biotherapeutics, Inc. | Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| AU2002304965A1 (en) * | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| EP1824879B1 (en) * | 2004-07-09 | 2014-10-29 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| AU2008312580A1 (en) | 2007-10-16 | 2009-04-23 | Symphogen A/S | Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| TW201014602A (en) * | 2008-07-08 | 2010-04-16 | Abbott Lab | Prostaglandin E2 binding proteins and uses thereof |
| EP2370458B1 (en) | 2008-11-28 | 2014-10-15 | Zensun (Shanghai) Science and Technology Limited | Neuregulin peptides and their use |
| AU2010303443A1 (en) * | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2011119836A1 (en) | 2010-03-24 | 2011-09-29 | Massachusetts Institute Of Technology | Methods and compositions for cardioprotection and cardioregeneration |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CN105849125B (zh) * | 2013-11-07 | 2020-05-15 | 国家医疗保健研究所 | 神经调节蛋白变构抗her3抗体 |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| KR102445502B1 (ko) * | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| BR112019005001A2 (pt) | 2016-09-15 | 2019-06-04 | Universität Stuttgart | proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral |
| FI3774859T3 (fi) | 2018-04-11 | 2024-05-24 | Salubris Biotherapeutics Inc | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät |
-
2019
- 2019-04-11 FI FIEP19723548.4T patent/FI3774859T3/fi active
- 2019-04-11 TW TW108112630A patent/TWI834654B/zh active
- 2019-04-11 PL PL19723548.4T patent/PL3774859T3/pl unknown
- 2019-04-11 MX MX2020010740A patent/MX2020010740A/es unknown
- 2019-04-11 EP EP24161673.9A patent/EP4361177A3/en active Pending
- 2019-04-11 KR KR1020207032449A patent/KR102949228B1/ko active Active
- 2019-04-11 HU HUE19723548A patent/HUE066892T2/hu unknown
- 2019-04-11 CA CA3096420A patent/CA3096420A1/en active Pending
- 2019-04-11 ES ES19723548T patent/ES2980163T3/es active Active
- 2019-04-11 DK DK19723548.4T patent/DK3774859T3/da active
- 2019-04-11 JP JP2020556258A patent/JP7575272B2/ja active Active
- 2019-04-11 EA EA202092458A patent/EA202092458A1/ru unknown
- 2019-04-11 IL IL322374A patent/IL322374A/en unknown
- 2019-04-11 BR BR112020020646-6A patent/BR112020020646A2/pt unknown
- 2019-04-11 WO PCT/US2019/026889 patent/WO2019200033A1/en not_active Ceased
- 2019-04-11 TW TW113107264A patent/TWI888027B/zh active
- 2019-04-11 IL IL277790A patent/IL277790B2/en unknown
- 2019-04-11 SG SG11202009831UA patent/SG11202009831UA/en unknown
- 2019-04-11 US US16/381,206 patent/US11046741B2/en active Active
- 2019-04-11 MY MYPI2020005322A patent/MY204230A/en unknown
- 2019-04-11 EP EP19723548.4A patent/EP3774859B1/en active Active
- 2019-04-11 PT PT197235484T patent/PT3774859T/pt unknown
- 2019-04-11 CN CN202411003345.2A patent/CN118909141A/zh active Pending
- 2019-04-11 CN CN201980025049.3A patent/CN113166218B/zh active Active
- 2019-04-11 AU AU2019252262A patent/AU2019252262B2/en active Active
- 2019-04-11 PE PE2020001553A patent/PE20210111A1/es unknown
-
2020
- 2020-10-02 PH PH12020551648A patent/PH12020551648A1/en unknown
- 2020-10-09 CL CL2020002621A patent/CL2020002621A1/es unknown
- 2020-10-09 MX MX2025002112A patent/MX2025002112A/es unknown
- 2020-10-21 CO CONC2020/0012621A patent/CO2020012621A2/es unknown
-
2021
- 2021-05-21 US US17/327,494 patent/US11718652B2/en active Active
-
2023
- 2023-06-13 US US18/333,797 patent/US20230322877A1/en active Pending
- 2023-06-14 JP JP2023097663A patent/JP7631420B2/ja active Active
- 2023-12-20 AU AU2023285793A patent/AU2023285793B2/en active Active
-
2025
- 2025-02-05 JP JP2025017265A patent/JP2025072502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535727A5 (enExample) | ||
| FI3774859T3 (fi) | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät | |
| JP7358365B2 (ja) | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 | |
| JP7376490B2 (ja) | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 | |
| AU2020201323B2 (en) | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof | |
| CN100424175C (zh) | ErbB-3 用于肿瘤治疗的方法和组合物 | |
| CN107074928B (zh) | 新型猫促红细胞生成素受体激动剂 | |
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| JP2022511804A (ja) | Ｐｄ－ｌ１とｖｅｇｆを標的化する組換えタンパク質 | |
| CN107446045A (zh) | 一种抗her2的抗体、其药物组合物及用途 | |
| AU2016263808A1 (en) | Trispecific binding proteins and methods of use | |
| JP2009525762A (ja) | 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法 | |
| JP2022507606A5 (enExample) | ||
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| EP3833690B1 (en) | Recombinant bifunctional protein targeting cd47 and her2 | |
| CN105229025A (zh) | 位点特异性胰岛素缀合物 | |
| JP2005500052A5 (enExample) | ||
| WO2014166029A1 (zh) | 针对表皮生长因子受体的抗体 | |
| KR20150097304A (ko) | 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체 | |
| US20090214576A1 (en) | Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease | |
| JP2025509520A5 (enExample) | ||
| JP7649923B2 (ja) | ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用 |